Janet A. LaFlamme

Discovery of Potent, Nonsteroidal, and Highly Selective Glucocorticoid Receptor Antagonists

B. Paul Morgan, Andrew G. Swick, Diane M. Hargrove et al. · Journal of Medicinal Chemistry · 2002 · 60 citations · Full text

Medicinal Chemistry, Biochemistry, Functional Selectivity +13

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

Richard L. Elliott, Kimberly O. Cameron, Janice E. Chin et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 30 citations · Full text

Metabolic Syndrome, Medicinal Chemistry, Biochemistry +9

Structure–activity relationship studies on 2-heteroaryl-4-arylimidazoles NPY5 receptor antagonists

Richard L. Elliott, Robert M. Oliver, Janet A. LaFlamme et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 26 citations · Full text

Molecular Pharmacology, Drug Target, Medicine +5

Discovery of Potent, Non-Steroidal and Highly Selective Glucocorticoid Receptor Antagonists with Anti-Obesity Activity

B. Paul Morgan, Kevin Liu, Deepak Dalvie et al. · Letters in Drug Design & Discovery · 2004 · 15 citations

Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres

Marlys Hammond, Richard L. Elliott, Melissa L. Gillaspy et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 15 citations · Full text

Medicinal Chemistry, Npy Y5 Antagonists, Biochemistry +8